SCHEMBL7787451

SCHEMBL7787451

CC(C)NCCCCCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.55
PRMT1 Q99873 1/20 0.54
TSHR P16473 5/20 0.52
LMNA P02545 2/20 0.52
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
GPR84 Q9NQS5 8/20 0.48
PPARG P37231 7/20 0.48
PPARD Q03181 7/20 0.48
PPARA Q07869 7/20 0.48
HDAC11 Q96DB2 5/20 0.48
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MEN1 O00255 1/20 0.48
ESR1 P03372 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11412060 1.00 ADRA1A (0.55) ADRA1APRMT1TSHRLMNANFKB1
SCHEMBL14558105 1.00 ADRA1A (0.55) ADRA1APRMT1TSHRLMNANFKB1
SCHEMBL23901607 1.00 ADRA1A (0.55) ADRA1APRMT1TSHRLMNANFKB1
SCHEMBL14558118 1.00 ADRA1A (0.55) ADRA1APRMT1TSHRLMNANFKB1
SCHEMBL2333045 0.98 ADRA1A (0.52) ADRA1APRMT1TSHRLMNANFKB1
Stearic Acid SCHEMBL28318872 0.92 GPR84 (0.63) TSHRGPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL28318864 0.92 GPR84 (0.63) TSHRGPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL28319943 0.92 GPR84 (0.63) TSHRGPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL28319931 0.92 GPR84 (0.63) TSHRGPR84PPARGPPARDPPARA
Stearic Acid SCHEMBL28318938 0.92 GPR84 (0.63) TSHRGPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
US-20230159762-A1 NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION REVVITY HEALTH SCIENCES, INC. 2023-05-25 US disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 US disclosed
US-9764040-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2017-09-19 US disclosed
US-20170014523-A1 SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION PFIZER (US) 2017-01-19 US disclosed
US-9504669-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2016-11-29 US disclosed
US-20160022626-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION PFIZER (US) 2016-01-28 US disclosed
US-9169264-B2 Spliceostatin analogs and methods for their preparation PFIZER INC. (US) 2015-10-27 US disclosed
US-20140134193-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION PFIZER INC. (US) 2014-05-15 US disclosed
US-7419983-B2 e.g. 3-[{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione; sex-hormone related diseases; anticarcinogenic agent; endometriosis, uterine fibroids, polycystic ovarian disease NEUROCRINE BIOSCIENCES, INC. (US) 2008-09-02 US disclosed
US-20070191403-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2007-08-16 US disclosed
US-7176211-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-02-13 US disclosed
JP-2001072572-A SKIN PREPARATION FOR EXTERNAL USE NOEVIR CO LTD 2001-03-21 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022626-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION SF3B5, SNRPA1, SF3B1 ADRA1A 3774/4885PRMT1 1489/4885TSHR 2101/4885
US-20140134193-A1 SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION SF3B5, SNRPA1, SF3B1 ADRA1A 3774/4885PRMT1 1489/4885TSHR 2101/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ADRA1A 220/4885PRMT1 2995/4885TSHR 2355/4885
US-20070191403-A1 GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO GNRHR, GHRHR, LHCGR ADRA1A 165/4885PRMT1 596/4885TSHR 50/4885
US-20170014523-A1 SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION SF3B5, SF3B1, SNRPA1 ADRA1A 4049/4885PRMT1 96/4885TSHR 947/4885
US-20230159762-A1 NIR TO SWIR FLUORESCENT COMPOUNDS FOR IMAGING AND DETECTION SMARCD1, SMARCE1, SMARCB1 ADRA1A 3990/4885PRMT1 2588/4885TSHR 1178/4885
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ HAVCR2, CD44, ENGASE ADRA1A 3909/4885PRMT1 3505/4885TSHR 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.